Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS | P14324 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11429091 | 0.94 | FDPS (0.32) | FDPS | |
| Hydrochloric Acid SCHEMBL11426659 | 0.92 | FDPS (0.31) | FDPS | |
| SCHEMBL11429186 | 0.90 | FDPS (0.30) | FDPS | |
| SCHEMBL24897527 | 0.85 | — | — | |
| SCHEMBL11318762 | 0.79 | FDPS (0.37) | FDPS | |
| SCHEMBL27714557 | 0.78 | — | — | |
| SCHEMBL4618187 | 0.77 | — | — | |
| SCHEMBL435430 | 0.77 | — | — | |
| SCHEMBL8367436 | 0.76 | FDPS (0.31) | FDPS | |
| SCHEMBL1678571 | 0.76 | FDPS (0.38) | FDPS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111454312-A | Preparation method of P2Y2 receptor agonist diquafosol tetrasodium | 中国药科大学 | 2020-07-28 | — | — | CN | disclosed |
| EP-1888610-A1 | STABILIZATION OF TRIFLATED COMPOUNDS | Amicus Therapeutics, Inc. (US) | 2008-02-20 | — | — | EP | disclosed |
| US-20060293508-A1 | Stabilization of triflated compounds | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2006-12-28 | — | — | US | disclosed |
| WO-2006133448-A1 | STABILIZATION OF TRIFLATED COMPOUNDS | AMICUS THERAPEUTICS, INC. (US) | 2006-12-14 | — | — | WO | disclosed |
| US-4201725-A | TRISUBSTITUTED METHYL-N-METHYLAMINE, PARKINSON*S DISEASE, ANTISPASMODIC AGENTS | LABAZ (FR) | 1980-05-06 | — | — | US | disclosed |
| US-4057644-A | PARKINSON'S DISEASE | LABAZ (FR) | 1977-11-08 | — | — | US | disclosed |
| US-4048334-A | PARKINSON*S DISEASE, NEUROLEPTIC AGENTS | LABAZ (FR) | 1977-09-13 | — | — | US | disclosed |
| US-4026925-A | PARKINSON*S DISEASE | LABAZ (FR) | 1977-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060293508-A1 | Stabilization of triflated compounds | MGAM, DTYMK, GCK | FDPS 257/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.